Table 4.
KCCQ Score | ≤74.5 | 74.6–91.7 | 91.8–99.0 | >99 | |||
---|---|---|---|---|---|---|---|
| |||||||
OR (95% CI) | p | OR (95% CI) | P | OR (95% CI) | P | ||
Unadjusted | 6.77 (3.75 – 12.23) | <0.001 | 4.54 (2.49 – 8.28) | <0.001 | 1.68 (0.86 – 3.30) | 0.13 | ref |
Demographic Variables* | 6.17 (3.40 – 11.18) | <0.001 | 3.99 (2.18 – 7.31) | <0.001 | 1.53 (0.78 – 3.01) | 0.22 | ref |
Clinical Variables** | 3.67 (1.90 – 7.10) | <0.001 | 2.64 (1.37 – 5.07) | 0.004 | 1.35 (0.66 – 2.77) | 0.41 | ref |
Clinical Variables and NTproBNP*** | 3.69 (1.88 – 7.27) | <0.001 | 2.67 (1.37 – 5.21) | 0.004 | 1.42 (0.68 – 2.95) | 0.35 | ref |
Clinical Variables, NT-proBNP, LVH, and LV systolic dysfunction**** | 3.30 (1.66 – 6.52) | 0.001 | 2.18 (1.11 – 4.29) | 0.02 | 1.23 (0.58 – 2.61) | 0.58 | ref |
Adjusted for age, sex, ethnicity and site.
Adjusted for age, sex, ethnicity, site, diabetes status, history of cardiovascular disease, current smoking, alcohol use, 24-hour urine protein, estimated glomerular filtration rate, systolic blood pressure, body mass index, low-density lipoprotein and high-density lipoprotein levels.
Adjusted for above plus NT-proBNP level.
Adjusted for above plus LVH and LV systolic dysfunction
Abbreviations: KCCQ: Kansas City Cardiomyopathy Questionnaire; NT-proBNP: N-terminal pro-brain natriuretic peptide; OR: odds ratio; CI: confidence interval; LVH: left ventricular hypertrophy; ref.: reference quartile.